WO2000012144A1 - A composition capable of absorbing fluid - Google Patents
A composition capable of absorbing fluid Download PDFInfo
- Publication number
- WO2000012144A1 WO2000012144A1 PCT/DK1999/000451 DK9900451W WO0012144A1 WO 2000012144 A1 WO2000012144 A1 WO 2000012144A1 DK 9900451 W DK9900451 W DK 9900451W WO 0012144 A1 WO0012144 A1 WO 0012144A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- water
- gel
- polymers
- polymer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
- C08J3/246—Intercrosslinking of at least two polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2300/00—Characterised by the use of unspecified polymers
- C08J2300/14—Water soluble or water swellable polymers, e.g. aqueous gels
Definitions
- a composition capable of absorbing fluid capable of absorbing fluid.
- the present invention relates to a composition, which is capable of absorbing fluids and at the same time forming a coherent gel.
- the composition may be used as an absorber in wound care products, sanitary articles, continence care, ostomy care or as an absorber in general.
- Powders, pastes, or fibre dressings for wound care which are capable of forming gels or foams when contacted with aqueous fluid are disclosed in several publications. Most of the references disclose dried gels, e.g. calcium alginate fibres and powders/pastes comprising cross-linked swellable particles. Usually these compositions comprises particles or fibres of dried gels being capable of absorbing wound exudate, but during the absorption there is little or no interaction or cross-linking between the involved molecules, and thus the wetted material will have a poor cohesion. The gel forming process does not take place when the composition is absorbing wound exudate from a wound, but during the prepara- tion of the composition before application to the wound.
- dried gels e.g. calcium alginate fibres and powders/pastes comprising cross-linked swellable particles.
- these compositions comprises particles or fibres of dried gels being capable of absorbing wound exudate, but during the absorption there is little or no interaction or cross-linking between the involved
- European patent No. EP 0 048 323 discloses a wound treatment composition which comprises e.g. acrylpolymers and gellable polysaccharides. The compounds are brought in solution and mixed, and hereby form a gel. The gel is then dried and pulverised. When this powder is applied to a wound, the particles will swell absorbing the wound exudate, but remain insoluble and with no cohesion.
- EP 0 380 253 A2 is disclosed a method for preparing a gel formed-in-place in the wound.
- the gel is formed by adding two liquids to the wound, said liquids reacting to form a gel with high cohesion.
- the composition comprises an alginate (polysaccharide) and a cross-linking agent selected from di- or trivalent metal ions.
- wound care products being capable of adapting to the conformation of the individual wounds but they are difficult to remove from the wound in one piece and/or they have limited absorbing capacity.
- Dressings such as fibre dressings, foams and hydrocolloids are easily removed in one piece, but they usually have a predetermined shape and are thus not able to adapt to the specific conformation of the individual wounds.
- a wound care dressing being capable of fitting individually to wounds as well as being easy to remove from the wound without remains and, at the same time, having a high absorption.
- the present invention relates to a composition capable of forming a coherent gel when contacted with an aqueous fluid, said composition comprising a water soluble polymer, said polymer, when dissolved in an aqueous fluid forms a water insoluble gel, to a method of preparation of such a composition and the use of such a composition for forming, in situ in a wound, a water insoluble, coherent gel.
- the present invention relates to a composition capable of forming a coherent gel when contacted with an aqueous fluid, said composition comprising a water soluble polymer, said polymer, when dissolved in an aqueous fluid, forms a water insoluble gel, said composition being characterised in that comprises a non-aqueous mixture of at least two water soluble polymers or a salt thereof, said polymers having opposite charges and forming, when dissolved in an aqueous fluid, a water-absorbing, water-insoluble, coherent gel.
- the invention also relates to a method for the preparation of a composition capable of forming a coherent gel when contacted with an aqueous fluid, said composition comprising a water soluble polymer, said polymer, when dissolved in an aqueous fluid, forms a water insoluble gel, said composition being characterised in that comprises a non-aqueous mixture of at least two water soluble polymers or a salt thereof, said polymers having opposite charges and forming, when dissolved in an aqueous fluid, a water-absorbing, water-insoluble, coherent gel in which the water soluble polymers in the form of powders are mixed intimately, optionally together with a pharmaceutical ingredient.
- the present invention furthermore relates to the use of a composition capable of forming a gel when contacted with an aqueous fluid, said composition comprising at least two water soluble polymers which, when dissolved in an aqueous fluid, forms a water-absorbing, water-insoluble, coherent gel, said composition comprising a non-aqueous mixture of at least two water soluble polymers or salt thereof, said polymers having opposite charges for forming, in situ in a wound, a water-insoluble, coherent gel.
- the composition comprises at least two differ- ent polymers, said polymers having functional groups of opposite charges.
- the polymer used according to the present invention may be polyionic/polyfunc- tional polymers such as polysaccharides, synthetic or semi-synthetic polymers or cellular or extracellular materials. It is preferred to use polysaccharides.
- the composition according to the invention comprises at least two hydrophilic, water soluble polymers with opposite charged functional groups.
- these polymers When these polymers are brought in contact with an aqueous fluid, they begin to dissolve. As the polymers dissolves the opposite charged functional groups will form ionic links between the polymers, hereby forming a coherent gel, said gel being water insoluble, but water absorbing and water- swellable.
- the gel may have an extremely high cohesion due to the number of cross-linking points and the conformation of the polymers.
- a composition according to the invention when a composition according to the invention is applied to a wound, it will start absorbing exudate and forms a gel filling a wound cavity.
- the polysaccharides used according to the invention include ionically charged derivatives of cellulose such as CMC, ionically charged derivatives of hemicellulose, ionically charged derivatives of chitin, chitosan or derivatives thereof, ionically charged derivatives of starches, alginates, pectin/pectat or derivatives thereof, carboxy methyl glucan, hyaluronic acid, carragenans, ionically charged derivatives of glycomannan, xanthan, ionically charged derivatives of guar gum, ionically charged derivatives of locust bean gum, glucosamines, gluco- saminoglycans such as heparan sulphate, chondroitin sulphate or keratan sulphate, and proteins and polypeptides such as heparin or collagen.
- CMC ionically charged derivatives of cellulose
- hemicellulose ionically charged derivatives of hemicellulose
- polysaccharides such as CMC or other ionically charged cellulose derivatives, ionic charged chitin derivatives, chitosan or derivatives thereof, alginates, pectin/pectat, hyaluronic acid, carragenans, ionically charged derivatives of guar, glucosaminoglycans such as chondroitin sulphate, keratan sulphate or carboxy methyl glucan.
- CMC ionically charged cellulose derivatives
- ionic charged chitin derivatives chitosan or derivatives thereof
- alginates alginates
- pectin/pectat hyaluronic acid
- carragenans ionically charged derivatives of guar
- glucosaminoglycans such as chondroitin sulphate, keratan sulphate or carboxy methyl glucan.
- the polymers are preferably present in a water soluble form, which some polysaccharides only are, when they are present as a salt.
- CMC chitin derivatives chitosan or derivatives thereof, alginates, pectin/pectat, hyaluronic acid, carragenans, xanthan, derivatives of guar, derivatives of locust bean gum, glucosamines, glucosaminoglycans such as heparan sulphate, chondroitin sulphate or keratan sulphate.
- composition according to the invention comprises a mixture of anionic and cationic polymer in the ratio of 10/90 - 90/10, more preferred 20/80 - 80/20 and most preferred 70/30 - 30/70.
- Cationic functional group linked to a polymer according to the invention may e.g. be amines, phosphines or imines.
- the amine groups may be primary, secondary or tertiary amines.
- Anionic functional group linked to a polymer according to the invention may e.g. be groups such as phosphate, sulphate, thiosulphate, carboxyl or functional groups such as acid chlorides or anhydrides.
- a preferred embodiment of the invention comprises sulphate, carboxyl or phosphate as anionic groups, and primary amine groups as cationic groups attached to a polymer, preferably a polysaccharide.
- the polymers are only soluble in water when the functional groups are charged. This means that the polymers usually are in the form of a salt, such as sodium alginate instead of alginic acid.
- the polymer can be given a charge by treatment with a solubiliser to provide a polymer salt, which is then dried and pulverised.
- a solubiliser to provide a polymer salt, which is then dried and pulverised.
- the cationic and anionic polymer powders are blended with a solubiliser in a dry form. When the composition is wetted, the solubiliser will dissolve first, and then dissolve the polymers, whereafter the gel is formed by the cross-linking of the polymers.
- the composition may also comprise a solubiliser.
- the composition e.g. comprises alginic acid and chitosan glutamate
- the right amount of sodium hydroxide may be incorporated in the composition.
- the sodium hydroxide solubilises the alginic acid by turning it into sodium alginate. Solubilised sodium alginate and chitosan glutamate will then form a gel.
- a chitosan salt which is cationic in aqueous solution and carboxy methyl cellulose (CMC) salt and/or hyaluronic acid salt, which is anionic in aqueous solution.
- CMC carboxy methyl cellulose
- hyaluronic acid salt which is anionic in aqueous solution.
- the composition according to the invention can be used in different physical forms, e.g. as powder, granulate, paste/cream or as fibres.
- composition of the invention may be prepared by a mixing procedure known per se from mixing of dry constituents.
- the composition may be packed in metered quantities for single or multiple applications.
- the composition is used in the form of a wound care product such as a wound dressing.
- the composition according to the invention comprises both a cationic and an anionic charged polymer.
- the polymers are present in a powder form, where the powders are homogeneous mixed into a powder mixture. When the powder mixture is spread on an exuding wound, the polymers will absorb the wound exudate and begin to dissolve. The dissolved polymers will cross-link and form a coherent gel, adapting the same shape as the wound. The thus formed gel is water-insoluble, but water absorbing, and will continue to absorb wound exudate after the formation of the gel. When the dressing needs to be changed, the cohesion of the gel will be so high, that the gel can be removed in one piece from the wound.
- a strip of web e.g. gauze or cotton
- the strip does not necessarily cover all of the wound, but will extend across the limit of the wound at least at one side.
- the strip will be incorporated in the gel.
- the part of the strip extending from the wound area will provide a grip or handle, which can be used to lift off the gel without having to pick or peel in the wound to grip the gel.
- the polymer powders are homogeneously dispersed in a substantially non-aqueous, liquid carrier, giving a composition in the form of a more or less viscous cream/paste.
- the paste or cream is brought in contact with an exuding wound, absorbs the wound exudate and turns into a coherent gel.
- the polymers are present in the form of a fibre bandage.
- the polymers are dissolved and the fibre structure of the composition disappears and turns into a coherent gel.
- bandage consists of a gel made by dissolved fibres, there will be no fibres left in the wound when the dressing is removed from the wound.
- composition can be used as such or as a part of a wound dressing optionally covered with top a film and optionally a release liner.
- the composition comprises one polymer having functional groups of opposite charges.
- the polymer present can be poly- functional/polyionical with both anionic and cationic groups attached to the polymer.
- Such a polymer may be a polymer having both amines and acid groups attached to the polymer.
- composition could be sodium carboxy methyl chitosan acetate (a salt of carboxy methyl chitosan).
- the composition comprises one or more active ingredients, e.g. a pharmaceutical medicament.
- active ingredients e.g. a pharmaceutical medicament.
- Such pharmaceutical medicaments includes a cytochine such as a growth hormone or a polypeptide growth factor such as TGF, FGF, PDGF, EGF, IGF-1, IGF-2, colony stimulating factor, transforming growth factor, nerve stimulating growth factor and the like giving rise to the incorporation of such active substances in a form being apt to local application in a wound in which the medicament may exercise its effect on the wound, other medicaments such as bactehostatic or bactericidal compounds, e.g.
- a cytochine such as a growth hormone or a polypeptide growth factor such as TGF, FGF, PDGF, EGF, IGF-1, IGF-2, colony stimulating factor, transforming growth factor, nerve stimulating growth factor and the like giving rise to the incorporation of such active substances in a form being apt to local application in a wound in which the medicament may exercise its effect on the wound
- other medicaments such as bactehostatic or bactericidal compounds, e.g.
- iodine, iodopovidone complexes chloramine, chlorohexidine, silver salts such as sulphadiazine, silver nitrate, silver acetate, silver lactate, silver sulphate, silver sodium thiosulphate or silver chloride, zinc or salts thereof, metronidazol, sulpha drugs, and penicillin's, tissue- healing enhancing agents, e.g. RGD tripeptides and the like, proteins, amino acids such as taurine, vitamins such ascorbic acid, enzymes for cleansing of wounds, e.g.
- pepsin trypsin and the like
- proteinase inhibitors or metalloprote- inase inhibitors such as lllostat or ethylene diamine tetraacetic acid
- cytotoxic agents and proliferation inhibitors for use in for example surgical insertion of the product in cancer tissue and/or other therapeutic agents which optionally may be used for topical application
- pain relieving agents such as lidocaine or chincho- caine, emollients, retinoids or agents having a cooling effect which is also considered an aspect of the invention.
- Cao chitosans from Sonat YC - chitosans form Youngdeok Chitosan CO., LTD. CC - chitosan from Seafresh Chitosan CO., LTD. BEI - chitosan from Biopolymer Engineering Inc. SeaCure 343 from Pronova Biopolymers Sodium alginate from Danisco Ingredients Akucell 0701 from Akzo Nobel Sodium Hyluronate from Pronova Carrageenan from Hercules
- chitosan is used as cationic component.
- the chitosan was dispersed in water. Then, the chitosan was dissolved in the water by adding acetic acid to the dispersion turning the amino groups of chitosan from non-ionic R-NH 2 into cationic R-NH 3 + groups.
- the solution was freeze-dried and pulverised, providing a chitosan salt powder.
- the cationic powder is mixed until homogeneity with an anionic powder prepared in an analogous manner from CMC using NaOH. If not otherwise stated, the mixture was a ratio of 50 % of each polymer.
- EXAMPLE 2 Preparation of the gels according to the invention and determination of the influence of the viscosity of the cationic component on the absorption and cohesion.
- the gels according to the invention were prepared as disclosed in Example 1. The results of the test are listed below in Table 2.
- Dynamic viscosity 1% solution in 1 % acetic acid, capil ary viscosimeter.
- the different chitosan cations have different absorption and cohesion properties. It is thus possible to adjust the absorption and cohesion to a desired value.
- solubiliser has influence on the absorption and cohesion properties of the gel.
- composition of the invention still has a high absorption capacity after the gel is formed combined with a strong cohesion.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU52792/99A AU5279299A (en) | 1998-08-31 | 1999-08-25 | A composition capable of absorbing fluid |
EP99938200A EP1109584A1 (en) | 1998-08-31 | 1999-08-25 | A composition capable of absorbing fluid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199801094 | 1998-08-31 | ||
DKPA199801094 | 1998-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000012144A1 true WO2000012144A1 (en) | 2000-03-09 |
Family
ID=8100930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1999/000451 WO2000012144A1 (en) | 1998-08-31 | 1999-08-25 | A composition capable of absorbing fluid |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1109584A1 (en) |
AU (1) | AU5279299A (en) |
WO (1) | WO2000012144A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10003397A1 (en) * | 2000-01-27 | 2001-08-09 | Hartmann Paul Ag | Polyelectrolyte solid system, process for producing the same and wound dressing |
WO2003061538A1 (en) * | 2002-01-22 | 2003-07-31 | Johnson & Johnson Medical Limited | Particulate wound dressings |
CN101117392B (en) * | 2007-07-26 | 2011-02-09 | 复旦大学 | Natural amphoteric polyelectrolyte electric field sensitive aqueous gel and preparation method thereof |
CN102772821A (en) * | 2012-08-01 | 2012-11-14 | 苏州博创同康生物工程有限公司 | Absorbable and hemostatic multifunctional particle with tissue induction and preparation and application of multifunctional particle |
CN104353103A (en) * | 2014-10-16 | 2015-02-18 | 湖北杰明凯林科技有限公司 | Antibacterial medical hydrogel dressing and preparation method thereof |
CN104984402A (en) * | 2015-07-14 | 2015-10-21 | 青岛大学 | Preparation method for hydroxyethyl chitosan in-situ hydrogel |
US9687584B1 (en) | 2011-11-13 | 2017-06-27 | Cresilon, Inc. | In-situ cross-linkable polymeric compositions and methods thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0380253A2 (en) * | 1989-01-24 | 1990-08-01 | Minnesota Mining And Manufacturing Company | Alginate hydrogel foam wound dressing |
US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5578661A (en) * | 1994-03-31 | 1996-11-26 | Nepera, Inc. | Gel forming system for use as wound dressings |
-
1999
- 1999-08-25 EP EP99938200A patent/EP1109584A1/en not_active Withdrawn
- 1999-08-25 AU AU52792/99A patent/AU5279299A/en not_active Abandoned
- 1999-08-25 WO PCT/DK1999/000451 patent/WO2000012144A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0380253A2 (en) * | 1989-01-24 | 1990-08-01 | Minnesota Mining And Manufacturing Company | Alginate hydrogel foam wound dressing |
US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5578661A (en) * | 1994-03-31 | 1996-11-26 | Nepera, Inc. | Gel forming system for use as wound dressings |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10003397A1 (en) * | 2000-01-27 | 2001-08-09 | Hartmann Paul Ag | Polyelectrolyte solid system, process for producing the same and wound dressing |
US6936746B2 (en) | 2000-01-27 | 2005-08-30 | Paul Hartmann Ag | Polyelectrolyte solid system, method for the production thereof and a wound dressing |
WO2003061538A1 (en) * | 2002-01-22 | 2003-07-31 | Johnson & Johnson Medical Limited | Particulate wound dressings |
CN101117392B (en) * | 2007-07-26 | 2011-02-09 | 复旦大学 | Natural amphoteric polyelectrolyte electric field sensitive aqueous gel and preparation method thereof |
US9687584B1 (en) | 2011-11-13 | 2017-06-27 | Cresilon, Inc. | In-situ cross-linkable polymeric compositions and methods thereof |
US10850003B2 (en) | 2011-11-13 | 2020-12-01 | Cresilon, Inc. | In-situ cross-linkable polymeric compositions and methods thereof |
US11383005B2 (en) | 2011-11-13 | 2022-07-12 | Cresilon, Inc. | In-situ cross-linkable polymeric compositions and methods thereof |
CN102772821A (en) * | 2012-08-01 | 2012-11-14 | 苏州博创同康生物工程有限公司 | Absorbable and hemostatic multifunctional particle with tissue induction and preparation and application of multifunctional particle |
CN104353103A (en) * | 2014-10-16 | 2015-02-18 | 湖北杰明凯林科技有限公司 | Antibacterial medical hydrogel dressing and preparation method thereof |
CN104984402A (en) * | 2015-07-14 | 2015-10-21 | 青岛大学 | Preparation method for hydroxyethyl chitosan in-situ hydrogel |
CN104984402B (en) * | 2015-07-14 | 2016-10-05 | 青岛大学 | A kind of hydroxyethyl chitosan in-situ hydrogel for repairing corneal Ocular surface damage |
Also Published As
Publication number | Publication date |
---|---|
AU5279299A (en) | 2000-03-21 |
EP1109584A1 (en) | 2001-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5804213A (en) | Biologically active aqueous gel wound dressing | |
US20030148994A1 (en) | Hemostatic composition | |
EP0848621B1 (en) | Wound treatment composition | |
EP0994733B1 (en) | A method for preparing a non-fibrous porous material | |
EP0663212B1 (en) | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives | |
CA2412804C (en) | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives | |
US4956350A (en) | Wound filling compositions | |
EP1294413B1 (en) | Sprayable wound care compositions | |
US20090062849A1 (en) | Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells | |
CN109106974B (en) | Gel tissue plugging material, preparation method thereof and plugging product | |
AU2001259601A1 (en) | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives | |
US11413192B2 (en) | Hemostatic paste and methods of making thereof | |
Yu et al. | Antibacterial conductive self-healable supramolecular hydrogel dressing for infected motional wound healing | |
AU2001267697A1 (en) | Sprayable wound care compositions | |
JP2002512087A (en) | Solid borate-diol reaction products for wounds | |
JPH04505267A (en) | Improvements in or relating to pharmaceutical preparations | |
EP1109584A1 (en) | A composition capable of absorbing fluid | |
RU2249467C2 (en) | Medicinal material and products based upon this material | |
EP0206692A2 (en) | Topically administrable pharmaceutical compositions | |
US20020071861A1 (en) | System for dermal or transdermal application containing an iota-carrageenan and process for its preparation | |
Xu et al. | Etamsylate loaded oxidized Konjac glucomannan-ε-polylysine injectable hydrogels for rapid hemostasis and wound healing | |
JP3825411B2 (en) | Malic acid hydrogel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999938200 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09743799 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999938200 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999938200 Country of ref document: EP |